title: Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
abstract: BACKGROUND
  Therapeutic options are limited for infections because of Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae (CRE). Study aim was to compare the efficacy of colistin to tigecycline for the treatment of these types of infections.
  
  
  METHODS
  A retrospective study was conducted at the Detroit Medical Center. Adult patients with infections because of A baumannii or CRE in 2009 who received ≥2 doses of colistin or tigecycline were studied. Risk factors, outcomes, and costs were analyzed.
  
  
  RESULTS
  There were 82 patients with infections because of A baumannii, 12 with CRE, and 12 with A baumannii and CRE coinfection. Seventy-one patients received colistin, 16 received tigecycline, and 19 received both colistin and tigecycline. Seven isolates were nonsusceptible to colistin and 79 to tigecycline. Patients receiving colistin alone or in combination were more likely to die during their hospitalization than patients receiving only tigecycline (P = .002). However, patients receiving colistin had higher severity of acute illness and had notable delays in initiation of effective antimicrobial therapy (P < .001).
  
  
  CONCLUSIONS
  Compared with patients who received tigecycline alone, patients who received colistin alone or in combination had a higher severity of acute illness indices and delays in initiation of effective therapy. This increased severity of illness contributed to the increased rate of mortality among patients treated with colistin for A baumannii or CRE infections.
authors.affiliation: Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, MI, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Ku
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Judy
authors.initials: J
authors.lastname: Moshos
authors.forename: Suchitha
authors.initials: S
authors.lastname: Bheemreddy
authors.forename: Yujing
authors.initials: Y
authors.lastname: Wang
authors.forename: Ashish
authors.initials: A
authors.lastname: Bhargava
authors.forename: Michelle
authors.initials: M
authors.lastname: Campbell
authors.forename: Namir
authors.initials: N
authors.lastname: Khandker
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lephart
authors.forename: Teena
authors.initials: T
authors.lastname: Chopra
authors.forename: Kayoko
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Emily T
authors.initials: ET
authors.lastname: Martin
authors.forename: Odaliz
authors.initials: O
authors.lastname: Abreu-Lanfranco
authors.forename: Sorabh
authors.initials: S
authors.lastname: Dhar
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
authors.forename: Dror
authors.initials: D
authors.lastname: Marchaim
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015780:Carbapenems / Q000494:pharmacology; D016022:Case-Control Studies; D015331:Cohort Studies; D003091:Colistin / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000187:drug effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008824:Michigan; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D000078304:Tigecycline; D016896:Treatment Outcome; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D008911:Minocycline; D003091:Colistin